Inhibrx(US:INBX) Prnewswire·2025-11-14 11:00Core Insights - Inhibrx Biosciences, Inc. reported financial results for Q3 2025, highlighting the completion of the sale of INBRX-101 to Sanofi S.A. and the spin-off of Inhibrx as a standalone entity [1][4] - The company has two ongoing clinical programs, with positive topline results from the registrational trial of ozekibart (INBRX-109) in chondrosarcoma [2][9] - Inhibrx plans to submit a biologics license application to the U.S. FDA in Q2 2026 [6] Recent Corporate Highlights - On October 23, 2025, Inhibrx announced positive topline results from its trial of ozekibart in chondrosarcoma, demonstrating significant improvement in median progression-free survival compared to placebo [2][6] - Interim data from expansion cohorts in colorectal cancer and Ewing sarcoma show high response and disease control rates in heavily pretreated patients [6] Financial Results - As of September 30, 2025, Inhibrx had cash and cash equivalents of $153.1 million, down from $186.6 million as of June 30, 2025 [6] - Research and development expenses for Q3 2025 were $28.5 million, a decrease from $38.9 million in Q3 2024, primarily due to reduced process development and manufacturing activities [6][7] - General and administrative expenses were $5.3 million in Q3 2025, down from $7.9 million in Q3 2024, attributed to decreased legal and personnel-related expenses [6][7] - The net loss for Q3 2025 was $35.3 million, or $2.28 per share, compared to a net loss of $43.9 million, or $2.84 per share, in Q3 2024 [6][7] Summary of Financial Performance - Total revenue for Q3 2025 was $1.3 million, compared to $0.1 million in Q3 2024 [7] - Total operating expenses for Q3 2025 were $33.8 million, down from $46.8 million in Q3 2024 [7] - The company reported total liabilities of $140.6 million as of September 30, 2025, with stockholders' equity at $36.8 million [7]